drugset / Trial / NCT01057498

Safety Study of Nebulized RNS60 to Treat Asthma.

NCT01057498

Phase 1 Completed 36 enrolled Revalesio Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is two-fold. First, to determine whether nebulized RNS60 is safe in healthy human subjects and in subjects with mild asthma, in a single-dose administration. Second, to determine whether nebulized RNS60 is safe in human subjects with mild-to-moderate asthma over a 4-week period.

Timeline

Start
2010-05
Primary completion
2010-11
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject RNS60 Other / unclassified 4 ml Other

Indications